Skye Bioscience (SKYE)
(Delayed Data from NSDQ)
$3.79 USD
+0.16 (4.41%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $3.80 +0.01 (0.26%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Skye Bioscience, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
SKYE 3.79 +0.16(4.41%)
Will SKYE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SKYE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SKYE
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
SKYE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for SKYE
Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August ...
Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab Dosing
JMP Securities Reiterates Market Outperform Rating for Skye Bioscience (SKYE) | SKYE Stock News
Citizens JMP Sticks to Their Buy Rating for Skye Bioscience (SKYE)
Skye (SKYE) Explores Nimacimab's Role in Obesity Treatment at Evercore Event | SKYE Stock News